SELPLG and Alzheimer disease: Interestingly, treatment with the specific T helper 2 (Th2)-targeting agents dupilumab and tralokinumab has been shown to influence the proliferation and cytokine production of circulating CLA+ T cells, highlighting potential CLA+ T-cell responses to gain insights into treatment efficacy in AD patients [10,11,12,13].